

**FROST BROWN TODD LLC**

2200 PNC CENTER  
201 EAST FIFTH STREET  
CINCINNATI, OH 45202  
(513) 651-6800  
FAX COVER SHEET

**OFFICIAL****Facsimile Transmission****Date:** Monday, April 19, 2004**Number of pages:** 33

(Including this cover page.)

**RECEIVED  
CENTRAL FAX CENTER****APR 19 2004**

To ..... Examiner Weber  
Company .....  
Fax Number ..... 220474345917038729306  
Voice Number .....

From ..... KAREN S. KRUEZKAMP  
Voice Number .....

---

**COMMENTS**

---

---

THIS FAX IS CONFIDENTIAL AND IS FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED. IT MAY CONTAIN INFORMATION THAT IS PRIVILEGED, ATTORNEYS' WORK PRODUCT AND/OR EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT (OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT), ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US BY COLLECT TELEPHONE.

---

**CINCINNATI FAX NUMBER: (513) 651-6981    OTHER OFFICES (FAX NUMBERS)**

LOUISVILLE (502) 581-1087  
COLUMBUS (614) 464-1737  
LEXINGTON (859) 231-0011  
MIDDLETOWN (513) 422-3010  
NASHVILLE (615) 251-5551  
NEW ALBANY (812) 948-7994

**OFFICIAL****RECEIVED  
CENTRAL FAX CENTER****PATENT****APR 19 2004****RESPONSE UNDER  
37 CFR §1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP NO.  
1651****IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

Applicant: Gregory Grabowski, : Paper No:  
Hong Du

Serial No. 09/775,517 : Group Art Unit: 1651

Filed: February 2, 2001 : Examiner: Jon Weber

Docket 10872/474345 Customer No. 26874  
No.

For: LIPID HYDROLYSIS THERAPY FOR ATHEROSCLEROSIS AND RELATED DISEASES

**MAIL STOP AF**  
**Commissioner for Patents**  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SECOND RESPONSE AFTER FINAL REJECTION**

Dear Sir:

In response to the Office Action of October 30, 2003, placing the above-cited application under final rejection, please consider the additional remarks and the second attached Declaration under 37 CFR 1.132 of David Hui, Ph.D., as requested by the Examiner.

As an initial matter, the Applicants wish to express their appreciation and gratitude to Examiner Weber for the interview of April 5, 2004, which was conducted between the Examiner, Dr. Gregory Grabowski and his undersigned Counsel. During that interview, Dr. Grabowski and his Counsel discussed with the Examiner the basis

of the Examiner's obviousness rejections. Dr. Grabowski also gave a presentation detailing the role of lysosomal acid lipase (LAL) in cholesteryl ester metabolism and hydrolysis. Agreement was reached between Applicants' counsel and the Examiner that the Applicants would submit a second response in which the Applicants would further discuss the enzymes described in the references cited by the Examiner in his 35 U.S.C. §103(a) rejections, and how these compare with Applicants' invention. The Applicants' arguments are summarized herein.